Similarly, increased levels of some biomarkers associated with CNS damage, such as the S100 B protein (protein calcium-binding B) and fibroglial acid protein (GFAP) have been observed during these post-COVID-19 neuropsychiatric manifestations [58]. Here, S100B is linked to COVID-19.